What Pharma Can Learn From Patients

A Global Patient Advocate Survey

Pharma want to engage with patients, but it is still not clear when and how this should happen. The struggle to attract and retain patients to clinical trials remains one of the major challenges in the drug development process.

MK&A and eyeforpharma surveyed a range of global patient advocacy groups and you can see the results and discussion of the outcomes in this whitepaper. 

The Whitepaper contains discussions of the survey findings from;
- Jeff Sherman, CMO, Horizon Pharma
- Jeanne Regnante, Executive Director, Head, Patient engagemeent strategy office, Office of the CPO, Merck & Co, Inc
- John Whyte, Director, Professional Affairs and Stakeholder Engagement, FDA
- Jane Reese-Coulbourne, Senior Consultant, MK&A

Please subscribe to view the analysis report